-$0.44 Earnings Per Share Expected for Savara Inc (NASDAQ:SVRA) This Quarter

Wall Street analysts forecast that Savara Inc (NASDAQ:SVRA) will announce earnings of ($0.44) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Savara’s earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.41). Savara reported earnings of ($0.37) per share in the same quarter last year, which would suggest a negative year over year growth rate of 18.9%. The business is expected to issue its next earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Savara will report full-year earnings of ($1.70) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.57). For the next financial year, analysts anticipate that the firm will post earnings of ($1.58) per share, with EPS estimates ranging from ($1.74) to ($1.28). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Savara.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05.

A number of analysts have recently issued reports on SVRA shares. LADENBURG THALM/SH SH reissued a “hold” rating and set a $1.00 target price on shares of Savara in a research note on Thursday, October 3rd. Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. ValuEngine raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Evercore ISI set a $17.00 target price on shares of Savara and gave the company a “buy” rating in a research note on Monday, August 12th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Savara has an average rating of “Hold” and a consensus target price of $9.09.

A number of large investors have recently added to or reduced their stakes in SVRA. Farallon Capital Management LLC lifted its stake in Savara by 43.3% in the second quarter. Farallon Capital Management LLC now owns 3,475,000 shares of the company’s stock worth $8,236,000 after acquiring an additional 1,050,000 shares during the period. Eversept Partners LP purchased a new stake in Savara in the second quarter worth about $574,000. BlackRock Inc. lifted its stake in Savara by 11.0% in the second quarter. BlackRock Inc. now owns 2,438,608 shares of the company’s stock worth $5,779,000 after acquiring an additional 241,117 shares during the period. Nomura Holdings Inc. purchased a new stake in Savara in the second quarter worth about $496,000. Finally, GSA Capital Partners LLP purchased a new stake in Savara in the second quarter worth about $206,000. 41.24% of the stock is owned by institutional investors.

NASDAQ SVRA traded up $0.01 on Monday, hitting $0.89. 203,500 shares of the stock were exchanged, compared to its average volume of 397,852. The company has a debt-to-equity ratio of 0.22, a quick ratio of 12.61 and a current ratio of 12.61. The stock has a fifty day moving average price of $1.71 and a two-hundred day moving average price of $4.84. The firm has a market capitalization of $35.22 million, a P/E ratio of -0.69 and a beta of 0.20. Savara has a 52-week low of $0.82 and a 52-week high of $11.96.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Recommended Story: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.